Diagnosis of tumour type allows prognostication and triage for biomarker testing (see the
Supplementary Material Section 3 and Supplementary Figure S1, available at https://doi …

Details on diagnostic procedures are covered in the Supplementary Material Section 2,
available at https://doi. org/10.1016/j. annonc. 2022.12. 009. See Supplementary Figure S1 …

Primary lung cancer remains the most common malignancy after non-melanocytic skin
cancer, and deaths from lung cancer exceed those from any other malignancy worldwide [1] …

Primary lung cancer remains the most common malignancy after non-melanocytic skin
cancer, and deaths from lung cancer exceed those from any other malignancy worldwide [1] …

Introduction IMpower110 previously revealed significant overall survival (OS) benefit with
atezolizumab versus chemotherapy in patients with treatment-naive EGFR-and ALK …

Primary lung cancer is the most common malignancy after non-melanocytic skin cancer, and
the leading cause of human cancer deaths worldwide [1]. While it has been the most …

Abstract The 1st ESMO Consensus Conference on lung cancer was held in Lugano,
Switzerland on 21 and 22 May 2010 with the participation of a multidisciplinary panel of …

Background The role of tumor mutational burden (TMB) is still debated for selecting
advanced non-oncogene addicted non-small-cell lung cancer (NSCLC) patients who might …

Non-small-cell lung cancer (NSCLC) accounts for 80%–85% of all lung cancer cases.
Approximately 90% of lung cancers among men and 80% among women are related to …

Background Anti-programmed cell death protein (death-ligand) 1 [PD-(L) 1] therapy alone
[cancer immunotherapy (CIT)-mono] or combined with platinum-based chemotherapy (CIT …